Back to top

Roivant Sciences (ROIV) Receives a Buy from Piper Sandler

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Roivant Sciences today and set a price target of $40.00. Rahimi covers the Healthca...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Roivant Sciences Ltd. (ROIV)